TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00937040

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: Optimal Patient Dose (placebo to match 18 mg - 72 mg) once daily by mouth for 6 weeks
Study: NCT01137123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant chemotherapy
Description: Docetaxel 75mg/m2 +Nedaplatin 75mg/m2,IV drip on day 1 of each 21 day cycle. Number of cycles: till unacceptable toxicity develops and no more than 4 cycles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard two field Lymphadenectomy
Description: Standard two field lymphadenectomy is standard mediastinal lymphadenectomy which defined by the International Association of esophageal disease(ISDE) of thoracic esophageal cancer.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard two field Lymphadenectomy
Description: Standard two field lymphadenectomy is standard mediastinal lymphadenectomy which defined by the International Association of esophageal disease(ISDE) of thoracic esophageal cancer.
Study: NCT04733196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Essential oils in combination with chlorhexidine 0,12%
Description: Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mouthwash
Description: Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0,20 % in combination with aroma oils
Description: Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide 0,8 %
Description: Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
Study: NCT01137123

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total two field Lymphadenectomy
Description: Total two field Lymphadenectomy is total mediastinal lymphadenectomy which defined by the International Association of esophageal disease(ISDE) of thoracic esophageal cancer.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total two field Lymphadenectomy
Description: Total two field Lymphadenectomy is total mediastinal lymphadenectomy which defined by the International Association of esophageal disease(ISDE) of thoracic esophageal cancer.
Study: NCT02781753

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Serum Albumin/interferon alpha2b
Description: Human Serum Albumin/interferon alpha2b fusion protein 300-1200 μg single dose S.C. at Day0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon 180 μg single dose S.C.
Description: Pegasys 180 mcg S.C. single dose on Day 0
Study: NCT02704520

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: High resolution MRI scan
Description: MRI reporting of tumour but not mrTRG in the control arm = standard of care

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High resolution MRI scan
Description: MRI reporting of tumour but not mrTRG in the control arm = standard of care

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mrTRG assessment
Description: Watch and wait offered for good responders Consider further treatment for poor responders
Study: NCT02622373

Intervention type: DEVICE
Intervention: PEA POD Infant Body Composition System
Description: The non-invasive device used in this study to measure a baby's body composition is a called a Pea Pod. The Pea Pod is a quick, safe, non-invasive and reliable bedside procedure used to measure changes in infant body composition.

Intervention type: DEVICE
Intervention: PEA POD Infant Body Composition System
Description: The non-invasive device used in this study to measure a baby's body composition is a called a Pea Pod. The Pea Pod is a quick, safe, non-invasive and reliable bedside procedure used to measure changes in infant body composition.

Intervention type: DEVICE
Intervention: PEA POD Infant Body Composition System
Description: The non-invasive device used in this study to measure a baby's body composition is a called a Pea Pod. The Pea Pod is a quick, safe, non-invasive and reliable bedside procedure used to measure changes in infant body composition.
Study: NCT03358589

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FDG-PET/CT
Description: Scans
Study: NCT01734538

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Complete

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Study: NCT01931579

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: confocal endo-microscopy
Description: The intervention consists of the use of confocal endo-microscopy using the CELLVIZIO device and either the 1 mm CELLVIZIO miniprobe (ALVEOFLEX) or the 0.6 mm CELLVIZIO miniprobe (CHOLANGIOFLEX), during a navigational bronchoscopy procedure for the diagnostic of peripheral nodule. In this study, the navigational device - either radial endobronchial ultrasound (EBUS) or electromagnetic navigation (EMN) - will be moved to another location if the CELLVIZIO displays a non solid pattern, indicating that the nodule may not have been reached during the procedure. Three attempts of EBUS or EMN are allowed until the CELLVIZIO shows a solid pattern.
Study: NCT00552773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclamen Europaeum
Description: Nasal spray 10% (V/V),one spray per nostril daily for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclamen Europaeum
Description: Nasal spray 10% (V/V),one spray per nostril daily for 7 days.
Study: NCT02638571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enhanced education on pulse use in complementary foods
Description: Enhanced Nutrition education with sessions and counseling by health extension workers
Study: NCT00220961

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone tablets - 45 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets similar to pioglitazone tablets - 1 tablet/day
Study: NCT02215733

Intervention type: DRUG
Intervention: ARB
Description: other than telmisartan
Study: NCT02638571

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: enhanced education on pulse use in complementary foods
Description: Enhanced Nutrition education with sessions and counseling by health extension workers
Study: NCT04616573

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OMNI® Surgical System
Description: Ab-interno transluminal viscoelastic delivery and trabeculotomy performed with the OMNI Surgical System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OMNI® Surgical System
Description: Ab-interno transluminal viscoelastic delivery and trabeculotomy performed with the OMNI Surgical System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iStent inject
Description: Trabecular meshwork implantation
Study: NCT04463056

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elizaria®
Description: Induction cycle: 600 mg (2 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes once a week for 4 weeks. Maintenance therapy: 900 mg (3 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes in Week 5, followed by 900 mg every 14 days.
Study: NCT02215733

Intervention type: DRUG
Intervention: ACEI

Intervention type: DRUG
Intervention: Beta-blockers

Intervention type: DRUG
Intervention: Diuretics

Intervention type: DRUG
Intervention: Telmisartan
Study: NCT00459303

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: aspherical intraocular lens
Description: implantation of aspherical intraocular lenses(AMO Tecnis Z9000)during cataract suregry (small cornea incision phacoemulsification, deliver with Monarch II device, in the bag implantation)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: spherical intraocular lens
Description: implantation of spherical intraocular lenses(Alcon SA60AT Acrysof)during cataract suregry (small cornea incision phacoemulsification, deliver with Monarch II device, in the bag implantation)
Study: NCT04398693

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotic
Description: It shall be a double-blinded, randomized, placebo-controlled crossover study and treatment with prebiotic for 4 weeks. After a washout period of 4 weeks, the study protocol will be repeated in the other arm. Participants will receive supplementary diet based on high-amylose cornstarch, which releases large amounts of SCFA (acetate and butyrate) in a sachet with a powder that must be dissolved in a glass of liquid to your choice, during 4 weeks (20 g 2x/day). Participants will undergo anthropometric, biochemistry and GUT microbiota assessment, before and after the end of the first phase of the crossover study. Later, when the inversion of the treatment groups occur all participants will also be subjected to the same procedures before and after the end of the second phase of the study.
Study: NCT03018743

Intervention type: DRUG
Intervention: Dapoxetine
Description: Patients receive dapoxetine (taken 1-3 hours before sexual intercourse) 30mg as needed. A dose escalation to 60mg will be consented after 1 month in case of low efficacy. Patients will be re-evaluated 1, 3, 6, 12, and 24 months after initiating therapy regarding the treatment status and the reasons for treatment discontinuation in the case of discontinuation. If patients missed any visits, they will be contacted by telephone or mail to collect their treatment data.
Study: NCT03091101

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scleral lens wearing keratoconics
Description: Cohort of keratoconics fitted with scleral lenses and monitored over 6 months
Study: NCT05505253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfacalcidol 0.0005 MG
Description: Alfacalcidol 0.5 mcg is given orally for 3 months, then vitamin D3 and vitamin D receptor levels are measured

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug is given orally for 3 months, then vitamin D3 and vitamin D receptor levels are measured
Study: NCT02319733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold
Description: Implantation of Bioresorbable vascular scaffold in vulnerable plaques
Study: NCT02500563

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Amino acid based infant formula

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed casein infant formula

Intervention type: OTHER
Group type: OTHER
Intervention: Mother's own breast milk
Study: NCT00841516

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was given the same way as a subcutaneous (just under the skin) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rBet v1-FV
Description: Placebo was given the same way as a subcutaneous (just under the skin) injection.
Study: NCT01225913

Intervention type: DRUG
Group type: OTHER
Intervention: fluticasone/salmeterol in all asthmatics
Description: budesonide 80ug/formoterol 4.5ug, 2 inhalations bid X 20-60 days or fluticasone 100ug/salmeterol 50ug, 1 inhalation bid X 20-60 days

Intervention type: DRUG
Group type: OTHER
Intervention: budesonide/formoterol or fluticasone/salmeterol in all asthmatics
Description: budesonide 160ug/formoterol 4.5ug, 2 inhalations bid or fluticasone 250ug/salmeterol 50ug, 1 inhalations bid
Study: NCT00735644

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Japanese encephalitis vaccine
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Japanese encephalitis vaccine
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Japanese encephalitis vaccine
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Japanese encephalitis vaccine (Acambis)
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Hepatitis A vaccine
Description: 0.5 mL, Intramuscular
Study: NCT03835936

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High frequency compression of the chest wall group
Description: The protocol in the high frequency compression of the chest wall group device consists of the Smart Vest® application, with a fixed frequency of 13 Hz and a time of 15 minutes. The selected mode will be the normal (fixed parameters) and the pressure of 4 units (12 cm H2O). The patient remains seated on his parents, and with a cotton garment between the vest and the skin of the patient to prevent skin lesions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual maneuvers physiotherapy group
Description: 20 minutes of manual maneuvers physiotherapy based on prolonged slow expiration: passive technique of expiratory help applied to the baby through a slow thoracic-abdominal pressure that begins at the end of spontaneous expiration and continues to the residual volume. The physiotherapist through the cough provoked or stimulation of the trachea gets expectoration of sputum, to be able to assess its weight.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual maneuvers physiotherapy group
Description: 20 minutes of manual maneuvers physiotherapy based on prolonged slow expiration: passive technique of expiratory help applied to the baby through a slow thoracic-abdominal pressure that begins at the end of spontaneous expiration and continues to the residual volume. The physiotherapist through the cough provoked or stimulation of the trachea gets expectoration of sputum, to be able to assess its weight.
Study: NCT01325649

Intervention type: PROCEDURE
Intervention: total mesorectal excision / long course radiochemotherapy
Description: long course 5-FU based radiochemotherapy before total mesorectal excision

Intervention type: RADIATION
Intervention: long course 5-FU bases radiochemotherapy
Study: NCT02587559

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: application of manual therapy techniques to upper extremity along with therapeutic exercise procedures to the axioscapular and rotator cuff musculature
Study: NCT04577313

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Self-Regulation Adherence Counseling
Description: Telephone-delivered counseling to focus on cognitive-behavioral skills to improve HIV treatment adherence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Self-Regulation Adherence Counseling
Description: Telephone-delivered counseling to focus on cognitive-behavioral skills to improve HIV treatment adherence.
Study: NCT04096989

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine regimen-based lifestyle mobile health APP
Description: The Experimental group receives TCM regimen-based lifestyle mobile health application intervention.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Lifestyle mobile health APP
Description: Sham comparator group receives mobile health application, but there is no traditional Chinese medicine information.
Study: NCT03214510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Given via thoracic epidural catheter or TAP block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Given via thoracic epidural catheter or TAP block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Given via thoracic epidural catheter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone Hydrochloride
Description: Given via thoracic epidural catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implanted Medical Device
Description: Undergo placement of thoracic epidural catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implanted Medical Device
Description: Undergo placement of ultrasound-guided, four-quadrant transversus abdominus plane block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: Given via TAP block

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Ancillary studies
Study: NCT02021539

Intervention type: PROCEDURE
Intervention: Cervical ultrasound +elastography 1
Description: Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.

Intervention type: BIOLOGICAL
Intervention: Vaginal fibronectin measurement
Description: Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.

Intervention type: DRUG
Intervention: Tocolytic treatment for 2 hours
Description: Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.

Intervention type: PROCEDURE
Intervention: Cervical ultrasound +elastography 2
Description: Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
Study: NCT00095823

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antidepressant + Placebo
Description: Antidepressant Caps/Tablets Placebo Tablets, Oral, 2-20 mg Placebo, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antidepressant + Aripiprazole
Description: Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-20 mg Aripiprazole, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
Study: NCT00617721

Intervention type: OTHER
Intervention: Blood withdrawal
Description: Observational study. Limited blood withdrawal. Any other intervention will be determined by the patient's clinical status.

Intervention type: OTHER
Intervention: Blood withdrawal
Description: Observational study. Limited blood withdrawal. Any other intervention will be determined by the patient's clinical status.
Study: NCT03842553

Intervention type: OTHER
Intervention: No Intervention: anonymous online survey
Study: NCT01137123

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: three field Lymphadenectomy
Description: Three field Lymphadenectomy includes abdominal,mediastinal and cervical lymphadenectomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: three field Lymphadenectomy
Description: Three field Lymphadenectomy includes abdominal,mediastinal and cervical lymphadenectomy.
Study: NCT03842553

Intervention type: OTHER
Intervention: No Intervention: anonymous online survey

Intervention type: OTHER
Intervention: No Intervention: anonymous online survey

Intervention type: OTHER
Intervention: No Intervention: anonymous online survey

Intervention type: OTHER
Intervention: No Intervention: anonymous online survey
Study: NCT00829608

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Papillomavirus Vaccine
Description: 0.5 mL of quadrivalent HPV vaccine will be given intramuscularly at three separate intervals. Dose 2 is given 2 weeks after dose 1 and dose 3 is given 4 weeks after dose 1 for a total of 3 doses over 2 months.
Study: NCT00518713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobazam Low Dose
Description: 0.25 mg/kg/day; tablets; orally; for 15-18 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobazam Medium Dose
Description: 0.5 mg/kg/day; tablets; orally; for 15-18 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobazam High Dose
Description: 1.0 mg/kg/day; tablets; orally; for 15-18 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets; orally; daily for 15-18 weeks
Study: NCT01051063

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2130579A
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2130579A
Description: Intramuscular injection
Study: NCT00836654

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Catumaxomab (Removab)
Description: Puncture free survival

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: paracentesis
Study: NCT00519636

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FPNS
Description: fluticasone propionate nasal spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FPNS
Description: fluticasone propionate nasal spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FFNS
Description: fluticasone furoate nasal spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FFNS
Description: fluticasone furoate nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo FFNS
Description: placebo nasal spray matching fluticasone furoate nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo FFNS
Description: placebo nasal spray matching fluticasone furoate nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo FPNS
Description: placebo nasal spray matching fluticasone propionate nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo FPNS
Description: placebo nasal spray matching fluticasone propionate nasal spray